The Fridley, Minn.-based medtech giant said that the Activa programming application, which is designed for use with Samsung Galaxy Tab S2 tablets, is intended to streamline workflows and improve clinician programming for its Activa DBS system.
Medtronic said that the programmer will enable upgrades to Activa rechargeable implantable neurostims that will extend their lifespans to 15 years, giving patients an additional six years before they need device replacement. The newly cleared programmer will also work with the company’s Activa DBS system designed to treat medically refractory epilepsy, which it expects to launch later this year.
“After using the Medtronic clinician programmer for the first time, I am impressed with the thoughtfulness put into the user interface. Its intuitive, visual interface and task-based workflow makes daily use easier, saving me time to focus on what’s most important-my patients,” Dr. Mohammad Maarouf of Germany’s Cologne Merheim Medical Center said in a prepared statement.
Medtronic said that it expects to initiate a launch of the programmer in the US before the end of July.
“This marks a new era of innovation from the only partner with a 25-year DBS legacy, and paves the way to our vision of the future of DBS with a fully integrated system from planning to programming. Additionally, this launch serves as evidence of our dedication to the Medtronic Mission and our DBS patients, with the extension of the device longevity of the ActivaRC rechargeable neurostimulator. Now patients can benefit from 6 extra years of therapy between surgeries, giving them even more time to do the things they love,” Medtronic brain modulation biz GM Mike Daly said in a press release
The DBS clinician programmer won CE Mark approval in the European Union in March, and a launch of the device is already underway in the region.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.